A medicine pathway has opened six months ahead of schedule, allowing MHRA licensing decisions and NICE value assessments to move together. The pathway celebrated by reaching a junction, studying the arrows and asking which one had been approved by the other arrow.
The aligned pathway is intended for qualifying medicines and aims to reduce the 90 day gap between marketing authorisation and NICE guidance. Suitable treatments may therefore reach patients sooner. Two important organisations can publish decisions together instead of passing paperwork between them like a parcel addressed to nobody who has ever accepted responsibility.
This is not a shortcut around evidence. MHRA remains responsible for deciding whether medicines work and are acceptably safe, while NICE continues to assess their value. The achievement is coordination, which sounds modest until you remember that a decision can spend three months waiting for another decision to complete its own decision.
Manufacturers taking part must engage early and follow the aligned timetable. They are encouraged to register products on UK PharmaScan well before marketing authorisation. The pathway has arrived early, but applicants are advised to prepare years in advance, giving the programme the reassuring logic of a surprise party whose invitations were sent before the guests were born.
‘We are aligning decisions,’ said Dr Phoebe Queuewell, Registrar of Properly Timed Things. ‘This is not magic. It is two important systems agreeing to meet without one sending a mysterious calendar invitation that the other system files under future possibilities.’
A joint scientific advice service is due to launch by April 2026, offering a single entry point for coordinated guidance. Until then, applicants can enjoy contacting two organisations separately to ask whether they are now one organisation, and whether the answer should be copied to the other one.
The aim is faster access without lowering the standard. That distinction matters. A better route should remove needless repetition, not spare evidence the inconvenience of being evidence. Otherwise the only thing being accelerated is the movement of reassuring language around a building.
At the launch, the pathway arrived early, found the correct corridor and waited outside a meeting room booked for a completely different reform. It was the most efficient thing in the building, so officials have now promoted it to chair the timetable review, where it will spend the next six months trying to find out whether the meeting has been approved by its own agenda.
Real story: Medicines and Healthcare products Regulatory Agency.
